Introduction
Secondary acute promyelocytic leukemia (APL) has been frequently reported as a late complication of chemotherapy (therapy-related APL [t-APL]) [1] [2] [3] . Topoisomerase II (topo-II)
inhibitors such as mitoxantrone (MTZ), epirubicin, adriamycin, and etoposide are the chemoterapic compounds most frequently associated with development of t-APL by inducing DNA double strand breaks [4] [5] [6] . Among them MTZ is the most commonly implicated agent 5, 6 . The latency between exposure to topo-II inhibitors and the development of t-APL is relatively short (< 3 years) and t-APL typically occurs without an antecedent myelodysplastic phase 3, 4 . Although t-APL developing after chemotherapy for a primary cancer has been reported frequently, only few cases of t-APL arising after treatment of non malignant diseases have been described so far. In the past few years, however, an increasing number of reports on t-APL occurring after multiple sclerosis (MS) have been published 5, 6 .
MS is a chronic autoimmune demyelinating disease of the central nervous system characterized by variable periods of relapse and remission of neurological symptoms and progression of disability over time. MTZ was the first immunosuppressive drug approved in the US and Europe as a single agent for treatment of relapsing-remitting (RRMS) or progressive MS 7 . We recently investigated at the genomic level, the location of DNA breakpoints in t-APL arising after MS. Interestingly, this analysis revealed a distinct distribution of chromosome 15 breakpoints as compared to de novo APL, biased towards disruption of chromosome 15 breakpoints within PML intron 6. Moreover, we reported that breakpoints in MTZ-treated cases fell at high frequency within an 8-bp region corresponding to a previously described "hotspot" identified in t-APL arising after treatment of breast cancer with regimens containing anthracyclines 8, 9 .
In the present study, we report on the presenting features and treatment outcome of 33 patients who developed APL on a background of MS, including 30 who received MTZ for their primary disease.
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Design and Methods
A call for studying t-APL cases was started in 2008 in the Italian GIMEMA group and extended subsequently to several European Centers. This study initially included the characterization at the genomic level of "hotspot" breakpoints in both PML and RARA genes.
Genomic studies of PML and RARA of 23/33 patients included in the present series have been reported in two separate articles 8, 9 , while the clinical features and outcome of 14/33 patients have been included in one of these previous reports 8 . MS patients received therapy according to the disease form as indicated 7 . The diagnosis of t-APL was confirmed in all cases by reversetranscriptase polymerase chain reaction (RT-PCR) or FISH detection of the PML-RARA hybrid gene 10 . FLT3 mutation screening for internal tandem duplications (ITD) was carried out as described 11 . APL was treated in all but one case with ATRA and anthracycline based combination chemotherapy induction according to treatment protocols active in various countries [12] [13] [14] [15] [16] .These protocols included the AIDA 2000 of the Italian GIMEMA study group 12 , the PETHEMA LPA2005 13 , and the PETHEMA LPA 99 14 , UK MRC AML15 15 and the German AMLCG 16 . All protocols received approval from the corresponding IRB and/or ethical committees. Patients were enrolled in the respective trials prospectively and were treated accordingly after signing informed consent. One patient (UPN 18) was treated without chemotherapy during induction, as detailed below (results section).
Unadjusted time-to-event analyses were performed using the Kaplan-Meier estimate 17 . The probability of relapse was also estimated by the cumulative incidence method (for marginal probability) 18, 19 . Overall survival (OS) was calculated from the date of starting induction therapy, while cumulative incidence of relapse (CIR) was calculated from the date of CR 20 . For CIR analysis, death in CR and development of secondary leukemia were considered as a competing cause of failure 18, 19 . For all estimates in which the event "relapse" was considered as an end point, hematologic and molecular relapse, as well as molecular persistence at the end of consolidation, were each considered as uncensored events 20 . Computations were performed using the 3D, 4F, 1L, and 2L programs from the BMDP statistical library (BMDP Statistical Software, Los Angeles, CA), and R 2.7.2 software package for CIR and Fine and Gray model.
Results and Discussion
Thirty-three patients with APL developed after MS are included in the study. Patient data were collected retrospectively from Italy (14 patients), Spain (10 patients), UK (3 patients),
Germany (3 patients), Greece (2 patients), and Austria (1 patient) as summarized in Table 1 .
Detailed information about the type of primary disease (MS) was available for 28 patients. MS was categorized as relapsing-remitting disease (N=16 cases), secondary progressive (N=8) and primary progressive (N=4). Thirty out of 33 patients were treated with MTZ for their primary disease and 21 of them were exposed to MTZ only, while 9 patients received more than one immunosuppressive agent. Three patients were not exposed to MTZ and received other treatments including steroids Data related to APL presenting features are summarized in Table 2 . The PML-RARA transcript type was available in 30 cases. Twenty-six (87%) patients had bcr1 (or "long" isoform) and 4 (13%) the bcr3 (or "short") transcript (Table 1) All 28 evaluable patients achieved molecular remission after consolidation and 20 of them received some type of maintenance as detailed in Table 3 . Compared to de novo APL, our patients had a predominance of females with a female/male ratio of 1.75. This finding most likely reflects the higher frequency of MS in females. As to the biologic characteristics, compared to de novo APL 12, 21 we found in this series a skewed distribution of PML-RARA isoforms with increased frequency of the bcr1 type. We believe that this finding might be correlated with the reported "hotspot" present in the PML gene intron 6 that appears to be more susceptible to MTZ-induced DNA breakpoints 7, 8 . Concerning other molecular lesions hereby analyzed, the frequency of FLT3-ITD was slightly inferior in MS-tAPL as compared to de novo APL.
t-APL typically occurs without an antecedent myelodysplastic phase and after a relatively short (< 3 years) latency period from exposure to topo-II inhibitors 3, 4 . Only few cases of t-APL arising after treatment of non-malignant diseases and in particular after MS have been described so far 5, 6 . Median time elapsed between the first exposure to MTZ and APL diagnosis was 32 months (range, 4-76 months), in keeping with latency reported for t-APL occurring after a primary tumor [1] [2] [3] .
With respect to treatment outcome, we observe that OS in this series was slightly inferior to that reported for de novo APL patients receiving current standard therapy 12, 13 . However, we remark that patients in this study were collected from several European countries and were not homogeneously treated, particularly as concerns the post-induction phase (Table 3 ). In particular, also in light of elevated MTZ cumulative doses previously given for MS, some investigators elected to decrease the amount of post-induction chemotherapy by omitting or substituting MTZ in consolidation. In fact, 2 of the 4 patients who relapsed did not receive anthracyclines in consolidation (UPN 28) or in maintenance (UPN 29) while the third patient (UPN 7) did not receive any maintenance based on the study protocol. Due to this level of heterogeneity and to the limited number of patients in this series, it is difficult to draw firm conclusions on the optimal treatment for MS-tAPL. However, the occurrence of 3 deaths due to treatment-related toxicity (including one in CR) and of one case of secondary AML may raise concerns on excessive exposure to chemotherapy and in particular to MTZ.
Recently, the PETHEMA group reported a cumulative incidence of sAML of 2.2% at 6 years for patients with de novo APL treated with standard ATRA and anthracycline-based chemotherapy 21 . In addition, the outcome of patients with t-APL after ATO containing front line therapy was found to be comparable to conventional induction therapy containing anthracyclines 22 .
It seems therefore reasonable, at least in the post-induction phase, to suggest the use of effective agents with different toxicity profile such as ATO for this particular subset of t-APLs, as well as for those APL cases developed after a primary cancer treated with chemotherapy. Financial and other disclosures provided by the authors using the ICMJE (www.icmje.org) Uniform
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